Add BrightSurf on Google Email

Weill Cornell Medicine


Mantle cell lymphoma treatment varies according to setting

The study found that autologous stem cell transplantation (ASCT) was underutilized in community settings, but maintenance therapy after standard therapy improved outcomes for patients over 65. Maintenance rituximab after bendamustine and chemotherapy regimens also significantly extended times to disease progression and overall survival.

SourceWeill Cornell Medicine·JournalJournal of Clinical Oncology·DateJun 28, 2022

New cancer subtype may illuminate treatment strategy

Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.

SourceWeill Cornell Medicine·JournalScience·DateMay 27, 2022

Benefits of PSA prostate cancer screening found to be more favorable than previous estimates, especially for blacks

New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...

SourceWeill Cornell Medicine·JournalNEJM Evidence·DateMay 15, 2022

Toxin-producing yeast strains in gut fuel IBD

Researchers at Weill Cornell Medicine found that certain Candida albicans yeast strains produce a potent toxin called candidalysin, which damages immune cells and triggers pro-inflammatory responses. The study suggests a possible way to personalize treatments for IBD patients by targeting these high-damaging strains.

SourceWeill Cornell Medicine·JournalNature·DateMar 16, 2022

Illuminating a biological light switch

Scientists at Weill Cornell Medicine developed a new imaging technique to capture bacteriorhodopsin's motions in response to light on a millisecond time scale. This study reveals the protein's kinetics, including the speed of transitions between open and closed states, which informs optogenetics research.

SourceWeill Cornell Medicine·JournalNature Communications·DateJan 26, 2022